Organization
Organization
International Bureau

(43) International Publication Date

15 April 2004 (15.04.2004)

PCT

(10) International Publication Number WO 2004/031172 A1

(51) International Patent Classification⁷: C07D 401/14.

(21) International Application Number:

211/58, A61K 31/4545

PCT/EP2003/011035

(22) International Filing Date: 6 October 2003 (06.10.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0223223.9

7 October 2002 (07.10.2002) GH

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ALBERT, Rainer [AT/CH]; Wartenbergstrasse 21, CH-4052 Basel (CH). COOKE, Nigel, Graham [GB/CH]; Tichelengraben 13, CH-4104 Oberwil (CH). THOMA, Gebhard [DE/DE]; Talweg 32, 79540 Lörrach (DB).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectuel Property, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.


(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS



(57) <u>Abstract</u>: Disclosed are compounds of formula (I) wherein R_1 , R_2 , R_3 and X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.